Clinical efficacy of milbemycin oxime in the treatment of nasal mite infection in dogs

• Published in: The Journal of the American Animal Hospital Association Vol. 35; no. 1; pp. 81 - 84
• Main Authors: Gunnarsson, L.K, Moller, L.C, Einarsson, A.M, Zakrisson, G, Hagman, B.G.J, Christensson, D.A, Uggla, A.H, Hedhammar, A.A
• Format: Journal Article
• Language: English
• Published: United States 1999
• Subjects: Administration, Oral; adverse effects; Animals; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; Dog Diseases - drug therapy; Dog Diseases - parasitology; Dogs; dosage; Female; Insecticides - administration & dosage; Insecticides - adverse effects; Insecticides - therapeutic use; Macrolides; Male; milbemycins; Mite Infestations - drug therapy; Mite Infestations - veterinary; Nose Diseases - drug therapy; Nose Diseases - parasitology; Nose Diseases - veterinary; oral administration; Sweden
• ISSN: 0587-2871; 1547-3317
• DOI: 10.5326/15473317-35-1-81

A multicentric clinical trial was done to evaluate the clinical efficacy of milbemycin oxime in the treatment of nasal mite (Pneumonyssoides caninum) infection in dogs. Milbemycin oxime was given to 70 dogs of different breeds, genders, and ages, with clinical signs associated with nasal mite infection. Twenty-five dogs had a verified infection, and 45 dogs had signs suggestive of nasal mite infection. Milbemycin oxime was given at the dosage of 0.5 to 1.0 mg/kg body weight orally once a week for three consecutive weeks. One month after initiation of treatment, 68 of the dogs had no more clinical signs associated with nasal mite infection.